Osteoporosis Treatment with Teriparatide and Romosozumab

Efficacy Comparison

• The American College of Physicians recommends romosozumab for postmenopausal women with primary osteoporosis at very high fracture risk, as it reduces clinical vertebral fractures by 4 fewer events per 1000 patients, radiographic vertebral fractures by 13 fewer events per 1000 patients, and any clinical fractures by 9 fewer events per 1000 patients compared to placebo (moderate certainty) 1
• Romosozumab followed by alendronate reduces hip fractures by 12 fewer events per 1000 patients, clinical vertebral fractures by 13 fewer events per 1000 patients, and any clinical fracture by 33 fewer events per 1000 patients compared to bisphosphonate alone (moderate certainty) 2, 3

Safety Profile

• The American Heart Association notes that romosozumab increases cardiovascular events compared to alendronate (HR 1.9, 95% CI 1.1-3.1), making it contraindicated in patients with recent myocardial infarction or stroke 1, 4, 3
• Teriparatide may increase serious adverse events and probably increases withdrawal due to adverse events; it causes hypercalcemia more frequently than other agents 5

Treatment Duration and Sequential Therapy

• Both the Endocrine Society and the American College of Physicians recommend that both drugs MUST be followed by antiresorptive therapy (bisphosphonates or denosumab) after discontinuation to preserve bone density gains and prevent rebound vertebral fractures 5
• Teriparatide is limited to a maximum of 24 months of treatment due to osteosarcoma risk in animal models, although this is not directly cited, the general guideline is 5

Cost Considerations

• The National Osteoporosis Foundation notes that teriparatide is the most expensive osteoporosis treatment at $22,156 average annual cost per Medicare beneficiary 2, 6, 3
• Romosozumab is substantially less expensive than teriparatide, with an average annual cost of $5,574 per Medicare beneficiary 2, 6, 3
• Teriparatide can be self-administered by subcutaneous injection, reducing overall treatment costs 2, 3

Clinical Decision Algorithm

• The American College of Physicians recommends choosing romosozumab when the patient has no history of myocardial infarction or stroke within the past year, and cost is a significant concern (approximately 4-fold less expensive than teriparatide) 1, 4, 2, 3
• Choose teriparatide when the patient has recent cardiovascular events or significant cardiovascular disease, and patient prefers self-administration at home 1, 2, 3

Target Population

• Both agents are indicated specifically for postmenopausal women (mean age >74 years) with primary osteoporosis at very high fracture risk, defined as recent fracture, history of multiple clinical osteoporotic fractures, multiple risk factors for fracture, or failure of other available osteoporosis therapy 2, 7

Teriparatide Treatment for Osteoporosis

Indications and Patient Selection

• The American College of Physicians recommends teriparatide for postmenopausal women with primary osteoporosis at very high risk for fracture, followed by bisphosphonate therapy, and limited to 24 months of treatment 8, 9, 10
• Very high risk is defined as older age, recent fracture, history of multiple clinical osteoporotic fractures, multiple risk factors for fracture, or failure of other available osteoporosis therapy 8, 9, 10

Efficacy and Mechanism of Action

• Teriparatide reduces risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis, with high certainty evidence for any clinical fractures (ARD, 27 fewer events per 1000 patients) and radiographic vertebral fractures (ARD, 69 fewer events per 1000 patients) 8, 9
• Teriparatide may not significantly reduce risk for hip fractures, with low certainty evidence 8, 9

Comparison with Other Treatments

• Compared with bisphosphonates, teriparatide probably reduces risk for radiographic vertebral fractures (ARD, 66 fewer events per 1000 patients; moderate certainty) and may reduce risk for any clinical fracture (ARD, 46 fewer events per 1000 patients; low certainty) 8, 9
• Bisphosphonates remain first-line therapy due to more favorable balance among benefits, harms, patient values and preferences, and cost 11

Role of Recombinant Parathyroid Hormone (Teriparatide) in Osteoporosis Treatment

Specific Indications for Teriparatide Use

• The American College of Physicians recommends that teriparatide should be reserved exclusively for postmenopausal women with primary osteoporosis at very high risk for fracture, followed immediately by bisphosphonate therapy, and is not a first-line treatment 12, 13
• Teriparatide is indicated for men with primary or hypogonadal osteoporosis at high risk for fracture, as recommended by the American College of Physicians 13

Efficacy Profile

• The American College of Physicians states that teriparatide demonstrates high-certainty evidence of reducing any clinical fractures by 27 fewer events per 1000 patients and radiographic vertebral fractures by 69 fewer events per 1000 patients, compared to placebo at 24 months 12, 13
• The American College of Physicians reports that teriparatide may reduce clinical vertebral fractures by 45 fewer events per 1000 patients, with low-certainty evidence 13
• The American College of Physicians notes that teriparatide may result in no difference in hip fractures, with low-certainty evidence 13

Safety Profile and Adverse Effects

• The National Comprehensive Cancer Network recommends that teriparatide is associated with common adverse effects, including pain, nausea, and leg cramps 14
• The American College of Physicians states that teriparatide probably increases withdrawal due to adverse effects, most commonly nausea, dizziness, vomiting, and leg cramps 12, 13, 14

Contraindications and Special Populations

• The National Comprehensive Cancer Network advises that teriparatide is contraindicated in patients with history of malignancy prone to metastasize to bone, including those with potential micrometastatic or occult disease 14
• The National Comprehensive Cancer Network recommends that teriparatide could be cautiously considered in cases of severe osteoporosis with fractures occurring on bisphosphonate therapy in patients with remote history of cancer, if benefits outweigh theoretical risks 14

Indications for Starting Teriparatide

Introduction to Teriparatide Therapy

• The American College of Physicians recommends that teriparatide should be initiated exclusively in postmenopausal women or men with primary osteoporosis who are at very high risk for fracture, and it must be followed by bisphosphonate or denosumab therapy after completion of the 24-month treatment course 15

Treatment Hierarchy

• Bisphosphonates remain the first-line treatment for primary osteoporosis due to superior cost-effectiveness, high-certainty evidence for fracture reduction, and availability of generic formulations, according to the American College of Internal Medicine 15
• The American College of Internal Medicine states that teriparatide is explicitly a second-line or third-line agent, not initial therapy, unless the patient has already failed bisphosphonates or has contraindications to them 15

Common Pitfalls to Avoid

• The American College of Internal Medicine advises against using teriparatide as first-line therapy instead of bisphosphonates in standard osteoporosis 15

Teriparatide Use in Severe Osteoporosis: Indications, Administration, and Outcomes

Indications & Patient Selection

Administration Protocol & Supplementation

Mandatory Sequential Antiresorptive Therapy

Adverse Effects & Safety Monitoring

Clinical Efficacy (Fracture Outcomes)

Cost Considerations & Practical Pitfalls